Compare Johnson & Johnson (JNJ) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Raymond James Financial, Inc. — how do they compare? Johnson & Johnson trades at $249.2 (market cap $598.96B), while Raymond James Financial, Inc. trades at $169.44 (market cap $32.80B). The key difference: Johnson & Johnson is far larger — about 18.3× Raymond James Financial, Inc.'s market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JNJ | RJF | |
|---|---|---|
Market Cap | $598.96B | $32.80B |
Volume | 6,156,228 | — |
Sector | Health | Financials |
52-Week High | $267.24 | $176.43 |
52-Week Low | $164.36 | $140.89 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | 1.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Raymond James Financial (RJF) trades at $168.23, down slightly by 0.08% on the day. The stock shows a bullish technical trend with moving averages supporting upside momentum, while recent earnings beats and steady revenue growth highlight fundamental strength. Analyst consensus is positive with a $176.83 price target, and the company declared a $0.54 dividend payable in July 2026.
Outlook remains favorable given consistent earnings performance and strong analyst support, though rising expenses and market volatility pose risks. The stock's current valuation metrics, including a P/E of 15.9, suggest room for growth if execution continues. Key catalysts include upcoming Q2 2026 earnings and sustained advisor network expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
